XIST and osteosarcoma: We plan to analyze the value of BMSCs derived exosomal XIST as a disease biomarker and for postoperative monitoring, as well as preclinical research and clinical research results, which will provides a theoretical basis for the development of new treatment strategies, especially for osteosarcoma patients with lung metastatic and with poor prognosis.